Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 30.00 | |
5 mg | In stock | $ 61.00 | |
10 mg | In stock | $ 79.00 | |
25 mg | In stock | $ 129.00 | |
50 mg | In stock | $ 166.00 | |
100 mg | In stock | $ 287.00 | |
200 mg | In stock | $ 430.00 | |
500 mg | In stock | $ 713.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. |
Targets&IC50 | c-Kit:2662 nM, PDGFRβ:307.6 nM, c-ABL:1.2 nM |
In vitro | In higher concentration, HH-GV-678 can inhibit the phosphorylation of c-Kit in Mo7e cell and the phosphorylation of PDGFR in Swiss3T3 cell, however, HH-GV-678 has no or little effect on other tyrosine kinases including EGFR, KDR, c-Src and HER2. HH-GV-678 can predominantly inhibit the autophosphorylation of Bcr-Abl in K562 cell. Flumatinib effectively overcame the drug resistance of certain KIT mutants with activation loop mutations (i.e., D820 g, N822K, Y823D, and A829P). |
In vivo | The purpose of this study was to identify the metabolites of flumatinib in CML patients, with the aim of determining the main metabolic pathways of lumatinib in humans after oral administration. Ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry revealed 34 metabolites; 7 primary metabolites were confirmed by comparison with synthetic reference standards. The results show that the parent drugflumatinib was the main form recovered in human plasma, urine, and feces. The main metabolites of flumatinib in humans were the products of N-demethylation, N-oxidation, hydroxylation, and amide hydrolysis |
Synonyms | HHGV678 |
Molecular Weight | 562.59 |
Formula | C29H29F3N8O |
CAS No. | 895519-90-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (88.87 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Flumatinib 895519-90-1 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl PDGFR c-Kit Inhibitor HHGV 678 HHGV-678 inhibit Platelet-derived growth factor receptor HHGV678 CD117 SCFR inhibitor